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15 ABSTRACT: Artemisinin−estrogen hybrids were for the first time both synthesized
16 and investigated for their in vitro biological activity against malaria parasites
17 (Plasmodium falciparum 3D7), human cytomegalovirus (HCMV), and a panel of
18 human malignant cells of gynecological origin containing breast (MCF7, MDA-MB-
19 231, MDA-MB-361, T47D) and cervical tumor cell lines (HeLa, SiHa, C33A). In
20 terms of antimalarial efficacy, hybrid 8 (EC50 = 3.8 nM) was about two times more
21 active than its parent compound artesunic acid (7, EC50 = 8.9 nM) as well as the
22 standard drug chloroquine (EC50 = 9.8 nM) and was, therefore, comparable to the
23 clinically used dihydroartemisinin (6) (EC50 = 2.4 nM). Furthermore, hybrids 9−12
24 showed a strong antiviral effect with EC50 values in the submicromolar range (0.22−
25 0.38 μM) and thus possess profoundly stronger anti-HCMV activity (approximately
26 factor 25) than the parent compound artesunic acid (7, EC50 = 5.41 μM). These
27 compounds also exerted a higher in vitro anti-HCMV efficacy than ganciclovir used as
28 the standard of current antiviral treatment. In addition, hybrids 8−12 elicited
29 substantially more pronounced growth inhibiting action on all cancer cell lines than their parent compounds and the reference
30 drug cisplatin. The most potent agent, hybrid 12, exhibited submicromolar EC50 values (0.15−0.93 μM) against breast cancer
31 and C33A cell lines.
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33Over the last three decades, steroids have become a prime34 focus of research in the field of medicinal chemistry due to
35 their remarkable and diverse pharmacological properties, such as
36 anticancer,1,2 anti-inflammatory,3,4 antiparasitic,5 and antiviral
37 activities.6,7 In particular, the two steroid hormones estrone (1)
f1 38 and 17β-estradiol (2) (Figure 1) attracted a lot of attention, as
39 these two estrogens are known to be involved in the development
40 of various cancer types such as breast, colorectal, prostate, and
41 ovarian cancer.8 This led to the discovery of many different
42 estradiol derivatives, which revealed to possess promising
43 anticancer activity. In 2003, fulvestrant (3), an estrogen receptor
44 antagonist, was approved in the USA for the treatment of
45 hormone-related breast cancer, and since then it has been used in
46 clinics.9 2-Methoxyestradiol (4), an endogenous metabolite of
47 17β-estradiol (2), turned out to effectively inhibit cancer cell
48 proliferation both in vitro and in vivo and is currently investigated
49 in advanced phases of clinical trials.10−15 One of the main
50advantages of 2-methoxyestradiol (4) over other biologically
51active estrogens is that it does not act as an estrogen receptor
52agonist and consequently is free of the typical hormone-related
53side effects.16,17 Furthermore, no serious toxicity was observed in
54clinical trials when 2-methoxyestradiol (4) was applied in
55pharmacological effective doses, and therefore, it can be regarded
56as a promising anticancer agent.16,18
57As of now, no artemisinin-estrogen hybrids were reported in
58the literature, and our working group already could obtain
59remarkable results applying the hybridization concept;19−22
60where two different biologically active substances are linked via a
61covalent bond,23,24 we planned to use estrogen derivatives as
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62 precursors for the synthesis of novel artemisinin hybrid
63 molecules. Since its isolation in 1972 from the plant Artemisia
64 annuaL. byYouyouTu, forwhich she received theNobel Prize in
65 2015, artemisinin (5) was intensively investigated for its
66 pharmacological activities.25,26 Artemisinin (5) exhibits not
67 only antimalarial activity, for what it was mainly used in
68 traditional Chinese medicine for several centuries,27−29 but it
69 also revealed to possess antiviral30−33 and anticancer effi-
70 cacy.34−38 These promising properties are also reflected in its
71 semisynthetic derivatives dihydroartemisinin (6)39−41 and
72 artesunic acid (7),42−45 bearing an alcohol or a carboxylic acid
73 functionality and for that reason appear to be well-suited for
74 hybridization purposes. Recently, it could be even demonstrated
75 in a phase I clinical trial, which was performed in patients with
76 metastatic breast cancer, that higher cumulative doses of
77 artesunic acid are safe and well tolerated.46
78 Herein, we present the synthesis of five novel artemisinin-
f2 79 estrogen hybrids 8−12 (Figure 2) and the evaluation of their in
80 vitro biological activity against malaria parasites (Plasmodium
81 falciparum 3D7), human cytomegalovirus (HCMV), and a
82 selection of human breast cancer cell lines (MCF7, MDA-MB-
83 231, MDA-MB-361, T47D) and cervical tumor cell lines (HeLa,
84 SiHa, C33A).
85 Results and Discussion. Chemistry. Hybrids 8 and 9 were
86 prepared in moderate to good yields (81%/45%) by standard
87amide coupling between estradiol amine 13 and either artesunic
88 s1acid (7) or artemisinin-derived carboxylic acid 15 (Scheme 1).
89The reaction was conducted at room temperature overnight in a
901:1 mixture of CH3CN and CH2Cl2 as solvent , and EDCI was
91solely used as coupling agent. Surprisingly, under these
92conditions no ester formation was observed as a side reaction,
93and the desired amides (8, 9) were the only products. The
94synthesis of the artemisinin-derived acid 15 was carried out in
95accordance to an already published protocol starting from
96 s2dihydroartemisinin (6) (Scheme 2).47 The special feature of this
97artemisinin derivative is that it is free of the O atom at C-10, and
98for that reason, it has been referred to a so-called C-10 nonacetal
99in the previous literature. This derivative has been considered to
100be more stable compared to the classical C-10-acetals such as
101artesunic acid (7).48 The other precursor, necessary for the
102synthesis of hybrids 8 and 9, 3-methoxy-estradiol-derived amine
10313 (Scheme 2), was also prepared in analogy to procedures
104described in the literature.49−51The stereoselectivity of themetal
105borohydride-mediated reduction of 16α-azido estrone 3-methyl
106ether (17) toward 17α- and 17β-estradiol derivatives 18a/b can
107be achieved by selecting different alkali metals (Li, Na, or K) as
108countercation. If bigger countercations like potassium are used,
109the 17β-isomer is predominantly formed (57% yield), whereas
110smaller countercations such as lithium lead almost exclusively to
111the formation of the 17α-isomer (59% yield). 16α-Azido 17β-
112estradiol 3-methyl ether (18b) was then converted to the desired
113amine 13 by hydrazine monohydrate mediated reduction
114catalyzed by Raney-Ni (95% yield). The synthesis of hybrid 10
115containing a 1,2,3-triazole linkage was realized by a copper-
116catalyzed 1,3-dipolar cycloaddition between 16α-azido estrone
1173-methyl ether (17) and artemisinin-derived alkyne 16, which
118afforded the desired product in 42% yield. Catalytic amounts of
119copper(II) sulfate and sodium ascorbate served as a source for
120copper(I), which was generated in situ. Alkyne 16 was prepared
121according to the literature by etherificationof dihydroartemisinin
122(6) with propargyl alcohol.52 As a final step, 3-benzyloxy-17β-
123hydroxy-16β-hydroxymethyl-estrone derivative 14 was reacted
124with either artesunic acid (7) or artemisinin-derived acid 15 in a
125Steglich esterification in order to yield the desired hybrids 11 and
12612 in 95/56%. DCC and DMAP were used as coupling agents
127andCH2Cl2 as solvent. The ester formation took place only at the
128primary alcohol group, which is probably attributed to its higher
129reactivity and less steric hindrance. The stability of target
Figure 1. Structures of estrone (1), 17β-estradiol (2), fulvestrant (3), 2-
methoxyestradiol (4), artemisinin (5), dihydroartemisinin (6), and
artesunic acid (7).
Figure 2. Novel hybrids 8−12 applied for biological tests against P. falciparum 3D7, HCMV, and breast and cervical cancer.
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130 compounds8−12was examined by heat exposure at 65 °C for 24
131 h or 40 °C for 48 h, respectively. After applying these conditions,
132
1H NMR spectroscopy revealed that all synthesized hybrids
133 remained sufficiently stable, i.e., less than 5% decomposition was
134 detected in the recorded spectra.
135 The hydroxy group at C-3 of all artemisinin-estrogen hybrids
136 8−12 was protected via an ether group (benzyloxy or methoxy)
137 to decrease the binding affinities of these novel compounds to the
138 estrogen receptors and consequently reduce eventual hormone-
139 related side effects.
140 Biological Activity of the Hybrids. Antimalarial Activity. All
141 synthesized hybrids 8−12 as well as their precursors,
142 dihydroartemisinin (6), artesunic acid (7), estrone diol 14, and
143 estrone azide 17 were investigated for their antimalarial activity
144 against chloroquine-sensitive Plasmodium falciparum 3D7 para-
t1 145 sites (Table 1). Hybrids 8−12 exhibited excellent to moderate
146 antimalarial efficacy with EC50 values ranging from 3.8 to 128.8
147 nM,while their estrogen precursors14 and17 showedno activity
148 (EC50 > 16,000 nM). The best performing hybrid 8 was roughly
149 two times more active than its parent compound artesunic acid
150(7) (EC50 = 8.9 nM) as well as the standard drug chloroquine
151(9.8 nM) and was therefore in terms of antimalarial efficacy
152comparable to the clinically used dihydroartemisinin (6) (EC50 =
1532.4 nM). Hybrids 9 and 12 containing a C-10 nonacetal
154artemisinin moiety were found to be two and four times,
155correspondingly, less active (EC50 values of 7.7 and 128.8 nM)
156than their C-10 acetal counterparts (EC50(8) = 3.8 nM;
157EC50(11) = 34.2 nM). The same behavior was also observed in
158connection with artemisinin-quinazoline hybrids,53 which is in
159contrast to that of artemisinin-derived dimers.54 This indicates
160that different mechanisms might be involved for artemisinin-
161derived hybrids than for its dimeric structures. In addition, these
162EC50 values also demonstrate that a benzyloxy subunit at C-3 of
163the estrogenmoiety (hybrids11 and12) seems tobeunbeneficial
164for antimalarial activity of artemisinin-estrogen hybrids, as
165compounds 8 and 9 with a methoxy group were much more
166active. This result might be explained by the fact that hybrids 11
167and 12 are more lipophilic than compounds 8 and 9, and as a
168result, their cellular uptake into the malaria parasites is probably
169more limited.
Scheme 1. Synthesis Route for Hybrids 8−12
Scheme 2. Synthesis of Estrogen Precursor 13 and Artemisinin-Derived Acid 15
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170 Anticytomegaloviral Activity. Furthermore, hybrids 8−12
171 were analyzed for antiviral activity, focusing on human
172 cytomegalovirus (recombinant HCMV AD169-GFP) used for
173 the infection of cultured primary human foreskin fibroblasts
174 (HFFs). Experimental determination of EC50 values was carried
175 out in accordance to a previously established protocol,55−58 and
176 the results thereof are summarized in Table 1. Hybrids 9−12
177 exerted a high antiviral efficacy with EC50 values in the
178 submicromolar range (0.22−0.38 μM) and thus possessed a
179 profoundly stronger anti-HCMV activity (approximately factor
180 25) than the parent compound artesunic acid (7). These
181 compounds were also more effective than ganciclovir used as the
182 gold standard of current antiviral treatment. In contrast to the
183 determined antimalarial activities, C-10 nonacetal-linked
184 artemisinin-derived hybrids 9 and 12 were more potent in anti-
185 HCMV activity than their C-10 acetal-linked counterparts
186 (hybrids 8 and 11). This difference was most pronounced
187 between compounds 8 and 9. In this case, hybrid 8 (EC50 = 2.44
188 μM)was approximately ten times less active than hybrid 9 (EC50
189 = 0.23 μM). Cell morphology, growth behavior, and signs of
190 cytotoxicity were routinelymonitored bymicroscopic inspection
191 under compound treatment along the period of infection (7 days,
192 referring to a situation of multiround viral replication), and no
193 cytotoxicity was observed within the range of all concentrations
194 tested.
195 Anticancer Activity. In a next step, hybrids 8−12 as well as
196 their artemisinin and estrone precursors were investigated for
197 their anticancer potential bymeans ofMTT assay against a panel
198 of humanbreast (MCF7,MDA-MB-231,MDA-MB-361, T47D)
199 and cervical (HeLa, SiHa, C33A) cancer cell lines (Table 1).
200 Estrone derivatives 13 and 14 exhibited antiproliferative action
201 similar to that of reference agent cisplatin in terms of potency,
202 while estrone azide 17 proved to be ineffective. Both artemisinin-
203 derived compounds 6 and 7 elicited growth inhibitory effects
204 comparable to cisplatin with exception for SiHa cell line, which
205 was not sensitive toward them. All of the synthesized hybrids 8−
206 12 exhibited substantially pronounced antiproliferative action on
207 breast cancer cells. The most potent hybrid 12 displayed
208 submicromolar EC50 values (0.18−0.93 μM) indicating an
209 outstanding increase in the efficacy when compared with the
210 actions of the building elements of the molecule. In the case of
211cervical cell lines, the actions of the precursors were modest, and
212the increase in the anticancer potency were less dynamic though
213compound 9 was remarkable on all utilized cells, and hybrid 12
214exhibited promising action on C33A cell line.
215Conclusion. In conclusion, several estradiol/estrone deriv-
216atives could be coupled to artemisinin for the first time, thereby
217forming five novel artemisinin-estrogen hybrids 8−12. These
218were investigated for their in vitro biological activity against
219malaria parasites (Plasmodium falciparum 3D7), human
220cytomegalovirus (HCMV), and a selection of human breast
221and cervical cancer cell lines. All synthesized hybrids exhibited a
222strong antimalarial effect with EC50 values in the nanomolar
223range (3.8−128.8 nM). The most active hybrid in terms of
224antimalarial efficacy, compound 8, was about two times more
225active than its parent compound artesunic acid (7) (EC50 = 8.9
226nM) as well as the standard drug chloroquine (9.8 nM) and was
227therefore comparable to the clinically used dihydroartemisinin
228(6) (EC50 = 2.4 nM). Furthermore, hybrids 9−12 exhibited high
229antiviral activity (EC50 = 0.22−0.38 μM) and thus represent a
230group of very attractive, novel chemical structures exerting a
231pronounced anti-HCMV activity mostly in the submicromolar
232range, which appears even superior to the in vitro efficacy of
233reference drug ganciclovir. Besides the antimicrobial properties
234of the prepared agents, they exhibited a pronounced growth
235inhibitory action against a panel of human cancer cells. EC50
236values of the hybrids were lower by orders of magnitude when
237compared with those of the building blocks. Based on the results
238of the presented antiproliferative assays, hybrid molecules
239designed and synthesized from artemisinin and estrone elements
240can be regarded as potential lead molecules for development of
241innovative anticancer agents. All in all, a relatively low level of
242effort in chemical synthesis was sufficient to generate very
243promising pharmacological candidate compounds, which once
244again highlights the attractiveness of the hybridization concept.
245We like to stress that this concept possesses a broad translational
246potential and might be useful for a number of future drug and
247biomedical developments.
Table 1. EC50 Values for Hybrids 8−12 and Selected Reference Compounds Tested against P. falciparum 3D7 Parasites, HCMV,
and Various Human Breast and Cervical Cancer Cell Lines
EC50 (μM)
e
compound MW (g/mol) EC50 (nM) P.f. 3D7 EC50 (μM) HCMV MCF7 MDA-MB-231 MDA-MB-361 T47D HeLa SiHa C33A
chloroquine 319.87 9.8 ± 2.8a
ganciclovir 579.98 2.60 ± 0.50b
cisplatin 300.05 5.78 19.13 3.76 9.78 12.43 7.87 3.69
artemisinin (5) 282.14 >10c - - - - - - -
DHA (6) 284.35 2.4 ± 0.4a >10c 8.24 10.69 1.71 4.60 10.46 29.80 1.71
artesunic acid (7) 384.42 8.9 ± 1.9 5.41 ± 0.60d 4.21 10.04 2.27 2.22 12.03 >30 1.83
estrone amine 13 301.43 - - 11.90 15.95 4.58 5.56 13.30 17.35 13.25
estrone diol 14 392.54 17,250 ± 586 - 12.89 12.75 2.77 8.32 12.80 7.75 12.20
estrone azide 17 325.41 >50,000 - >30 >30 >30 >30 >30 >30 >30
8 667.84 3.8± 0.8 2.44 ± 0.13 4.69 6.89 0.64 0.74 11.45 26.00 0.87
9 609.80 7.7 ± 2.4 0.23 ± 0.20 1.02 1.85 0.69 1.17 1.65 6.21 0.57
10 647.81 13.1 ± 1.8 0.24 ± 0.01 1.77 1.78 0.17 0.16 15.40 28.90 2.05
11 758.95 34.2 ± 3.2 0.38 ± 0.10 0.76 2.30 0.20 0.22 >30 28.43 1.73
12 700.91 128.8 ± 13.0 0.22 ± 0.00 0.45 0.86 0.18 0.93 14.22 16.12 0.15
aEC50 values have been previously reported.
19 bEC50 value has been previously reported.
43 cEC50 values have been previously reported.
dEC50 value
has been previously reported.58 eMean values from two independent determinations with five parallel wells.
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